Clopidogrel–Paclitaxel Drug–Drug Interaction: A Pharmacoepidemiologic Study

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 3, 2017, Pages 547-553

  Agergaard, K ^a   Mau Sorensen M ^b   Stage, T B ^a,c   Jorgensen T L ^d   Hassel, R E ^e   Steffensen, K D ^f   Pedersen, J W ^g   Milo, M L H ^h   Poulsen, S H ^b   Pottegard A ^a   Hallas, J ^a   Brosen K ^a,d   Bergmann, T K ^d,i  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f LILLEBAELT HOSPITAL   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ Hospital of South West Jutland   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CLOPIDOGREL; PACLITAXEL; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 2C8; TICLOPIDINE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG INTERACTION; DRUG MEGADOSE; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; NAUSEA AND VOMITING; NEUTROPHIL; OVARY CANCER; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SENSORY NEUROPATHY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DOSE RESPONSE; LIVER; METABOLISM; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGED; ASPIRIN; CYTOCHROME P-450 CYP2C8; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PHARMACOEPIDEMIOLOGY; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TICLOPIDINE;

EID: 85019672170     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.674     Document Type: Article

References (19)

1. Gianni, L. et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J. Clin. Oncol. 27, 2474–2481 (2009).
2. McGuire, W.P. et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23, 40–47 (1996).
3. Vasey, P.A. et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96, 1682–1691 (2004).
4. Weissman, C.H., Reynolds, C.H., Neubauer, M.A., Pritchard, S., Kobina, S. & Asmar, L. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6, 358–364 (2011).
5. Belani, C.P. et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann. Oncol. 16, 1069–1075 (2005).
6. Taxol prescribing information. Bristol-Myers Squibb. (2011). Accessed 4 February 2017.
7. de Graan, A.J. et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. 19, 3316–3324 (2013).
8. Joerger, M. et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 27, 1895–1902 (2016).
9. Mielke, S. et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11, 4843–4850 (2005).
10. Smorenburg, C.H., Sparreboom, A., Bontenbal, M., Stoter, G., Nooter, K. & Verweij, J. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J. Clin. Oncol. 21, 197–202 (2003).
11. Gianni, L. et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13, 180–190 (1995).
12. Bergmann, T.K. et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 11, 113–120 (2011).
13. Bergmann, T.K. et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin. Pharmacol. Toxicol. 110, 199–204 (2012).
14. Tornio, A. et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498–507 (2014).
15. Rahman, A., Korzekwa, K.R., Grogan, J., Gonzalez, F.J. & Harris, J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543–5546 (1994).
16. Bergmann, T.K., Filppula, A.M., Launiainen, T., Nielsen, F., Backman, J. & Brosen, K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma. Br. J. Clin. Pharmacol. 81, 313–315 (2016).
17. Shinoda, Y., Kimura, M., Usami, E., Asano, H. & Yoshimura, T. Potential drug interaction between paclitaxel and clopidogrel. Biomed. Rep. 5, 141–145 (2016).
18. Johannesdottir, S.A., Horvath-Puho, E., Ehrenstein, V., Schmidt, M., Pedersen, L. & Sorensen, H.T. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin. Epidemiol. 4, 303–313 (2012).
19. National Institutes of Health, N.C.I. Common Terminology Criteria for Adverse Events v4.03. (ed. Services, U.S.D.o.H.a.H.) (2010).